October 21, 2016
Nanobiotix’s partner, PharmaEngine launched a new NBTXR3 clinical trial in head and neck cancers
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.